ASCO 2018 - Chicago - Chronic Myeloid Leukemia
GENERAL INFORMATION
ASCO American Society of Clinical Oncology - June 1 - June 5, 2018 - McCormick Place, Chicago, Illinois
NEWS
Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML
June 3, 2018, Cancer Therapy Advisor
Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia
June 3, 2018, Cancer Therapy Advisor
Long-term treatment-free remission achievable for chronic myeloid leukemia
June 3, 2018, Healio
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
June 2, 2018, PR Newswire
Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML
June 3, 2018, Cancer Therapy Advisor
Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia
June 3, 2018, Cancer Therapy Advisor
Long-term treatment-free remission achievable for chronic myeloid leukemia
June 3, 2018, Healio
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
June 2, 2018, PR Newswire
VIDEOS
ASCO 2018 - Susan Branford about Applications for Next-Generation Sequencing
June 3, 2018, QIAGEN
ASCO 2018 - Susan Branford about Applications for Next-Generation Sequencing
June 3, 2018, QIAGEN
SOME INTERESTING ABSTRACTS ABOUT CML
Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.
Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.
Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP)
Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.
Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes
Long-term treatment-free remission (TFR) following frontline (1L) nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 144-wk results.
Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.
Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP)
Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib.
Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up.
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes